Proteasome inhibition induces stress kinase dependent transport deficits - Implications for Alzheimer's disease

Molecular and Cellular Neuroscience

Volumn 58, Issue , 2014, Pages 29-39

  Agholme, Lotta ^a,c   Nath, Sangeeta ^a   Domert, Jakob ^a   Marcusson, Jan ^a   Kågedal, Katarina ^a   Hallbeck, Martin ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Centre of Surgery and Oncology   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Axonal transport; C Jun; ERK 1 2; Proteasome dysfunction; Tau phosphorylation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEASOME; PROTEASOME INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELL DEATH; CELL STRUCTURE; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STABILITY; HUMAN; HUMAN CELL; MICROTUBULE; NERVE FIBER TRANSPORT; NEURITE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSPORT VESICLE;

ALZHEIMER'S DISEASE; AXONAL TRANSPORT; C-JUN; ERK 1/2; PROTEASOME DYSFUNCTION; TAU PHOSPHORYLATION;

ALZHEIMER DISEASE; AXONAL TRANSPORT; CELL LINE, TUMOR; HUMANS; LEUPEPTINS; MAP KINASE KINASE 4; MICROTUBULES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEURITES; PHOSPHORYLATION; PROTEASOME INHIBITORS; TAU PROTEINS;

EID: 84890676730     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2013.11.001     Document Type: Article

References (64)

1. Agholme L., Lindström T., Kågedal K., Marcusson J., Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J. Alzheimers Dis. 2010, 20:1069-1082.
2. Agholme L., Hallbeck M., Benedikz E., Marcusson J., Kågedal K. Amyloid-β secretion, generation, and lysosomal sequestration in response to proteasome inhibition: involvement of autophagy. J. Alzheimers Dis. 2012, 31:343-358.
3. Arnaud L.T., Myeku N., Figueiredo-Pereira M.E. Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. J. Neurochem. 2009, 110:328-342.
4. Biernat J., Mandelkow E.M. The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol. Biol. Cell 1999, 10:727-740.
5. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
6. Brown M.R., Bondada V., Keller J.N., Thorpe J., Geddes J.W. Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons. J. Alzheimers Dis. 2005, 7:15-24.
7. Chatterjee S., Sang T.K., Lawless G.M., Jackson G.R. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum. Mol. Genet. 2009, 18:164-177.
8. Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 2006, 6:579-595.
9. Clavaguera F., Bolmont T., Crowther R., Abramowski D., Frank S., Probst A., Fraser G., Stalder A., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
10. De Felice F.G., Wu D., Lambert M.P., Fernandez S.J., Velasco P.T., Lacor P.N., Bigio E.H., Jerecic J., Acton P.J., Shughrue P.J., Chen-Dodson E., Kinney G.G., Klein W.L. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol. Aging 2008, 29:1334-1347.
11. Delobel P., Leroy O., Hamdane M., Sambo A.V., Delacourte A., Buee L. Proteasome inhibition and tau proteolysis: an unexpected regulation. FEBS Lett. 2005, 579:1-5.
12. Drewes G., Ebneth A., Mandelkow E.M. MAPs, MARKs and microtubule dynamics. Trends Biochem. Sci. 1998, 23:307-311.
13. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 1998, 143:777-794.
14. Ferreira A., Lu Q., Orecchio L., Kosik K.S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Aβ. Mol. Cell. Neurosci. 1997, 9:220-234.
15. Flood F., Murphy S., Cowburn R.F., Lannfelt L., Walker B., Johnston J.A. Proteasome-mediated effects on amyloid precursor protein processing at the γ-secretase site. Biochem. J. 2005, 385:545-550.
16. Friguet B., Szweda L.I. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett. 1997, 405:21-25.
17. Goedert M., Cohen E.S., Jakes R., Cohen P. p42 map kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1 implications for Alzheimer's disease. FEBS Lett. 1992, 312:95-99.
18. Götz J., Eckert A., Matamales M., Ittner L., Liu X. Modes of Aβ toxicity in Alzheimer's disease. Cell. Mol. Life Sci. 2011, 68:3359-3375.
19. Grune T., Botzen D., Engels M., Voss P., Kaiser B., Jung T., Grimm S., Ermak G., Davies K.J.A. Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch. Biochem. Biophys. 2010, 500:181-188.
20. Hallbeck M., Nath S., Marcusson J. Neuron-to-neuron transmission of neurodegenerative pathology. Neuroscientist 2013, 19(6):560-566.
21. Hempen B., Brion J.P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1996, 55:964-972.
22. Ittner L.M., Ke Y.D., Götz J. Phosphorylated tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 2009, 284:20909-20916.
23. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5819-5824.
24. Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 2003, 85:115-122.
25. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 2000, 75:436-439.
26. King M.E., Kan H.M., Baas P.W., Erisir A., Glabe C.G., Bloom G.S. Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid. J. Cell Biol. 2006, 175:541-546.
27. Knecht E., Aguado C., Cárcel J., Esteban I., Esteve J., Ghislat G., Moruno J., Vidal J., Sáez R. Intracellular protein degradation in mammalian cells: recent developments. Cell. Mol. Life Sci. 2009, 66:2427-2443.
28. Laser H., Mack T.G.A., Wagner D., Coleman M.P. Proteasome inhibition arrests neurite outgrowth and causes "Dying-back" degeneration in primary culture. J. Neurosci. Res. 2003, 74:906-916.
29. Li B., Chohan M., Grundke-Iqbal I., Iqbal K. Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol. 2007, 113:501-511.
30. Li X., Du Y., Fan X., Yang D., Luo G., Le W. c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J. Neuropathol. Exp. Neurol. 2008, 67:933-944.
31. Lindwall G., Cole R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 1984, 259:5301-5305.
32. Liu Y.H., Wei W., Yin J., Liu G.P., Wang Q., Cao F.Y., Wang J.Z. Proteasome inhibition increases tau accumulation independent of phosphorylation. Neurobiol. Aging 2009, 30:1949-1961.
33. López Salon M., Morelli L., Castaño E.M., Soto E.F., Pasquini J.M. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J. Neurosci. Res. 2000, 62:302-310.
34. MacInnis B.L., Campenot R.B. Regulation of Wallerian degeneration and nerve growth factor withdrawal-induced pruning of axons of sympathetic neurons by the proteasome and the MEK/Erk pathway. Mol. Cell. Neurosci. 2005, 28:430-439.
35. Marambaud P., Chevallier N., Barelli H., Wilk S., Checler F. Proteasome contributes to the α-secretase pathway of amyloid precursor protein in human cells. J. Neurochem. 1997, 68:698-703.
36. Marambaud P., Ancolio K., Lopez-Perez E., Checler F. Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells. Mol. Med. 1998, 4:147-157.
37. Morfini G.A., Burns M., Binder L.I., Kanaan N.M., LaPointe N., Bosco D.A., Brown R.H., Brown H., Tiwari A., Hayward L., Edgar J., Nave K.-A., Garberrn J., Atagi Y., Song Y., Pigino G., Brady S.T. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 2009, 29:12776-12786.
38. Mudher A., Shepherd D., Newman T.A., Mildren P., Jukes J.P., Squire A., Mears A., Drummond J.A., Berg S., MacKay D., Asuni A.A., Bhat R., Lovestone S. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry 2004, 9:522-530.
39. Nath S., Agholme L., Kurudenkandy F.R., Granseth B., Marcusson J., Hallbeck M. Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid. J. Neurosci. 2012, 32:8767-8777.
40. Nixon R.A., Cataldo A.M. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J. Alzheimers Dis. 2006, 9:277-289.
41. Nunan J., Shearman M.S., Checler F., Cappai R., Evin G., Beyreuther K., Masters C.L., Small D.H. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from γ-secretase. Eur. J. Biochem. 2001, 268:5329-5336.
42. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:363-373.
43. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
44. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimers Dis. 2001, 3:41-48.
45. Pei J.J., Braak H., An W.L., Winblad B., Cowburn R.F., Iqbal K., Grundke-Iqbal I. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res. Mol. Brain Res. 2002, 109:45-55.
46. Perlson E., Maday S., Fu M.M., Moughamian A.J., Holzbaur E.L.F. Retrograde axonal transport: pathways to cell death?. Trends Neurosci. 2010, 33:335-344.
47. Perry G., Friedman R., Shaw G., Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3033-3036.
48. Ploia C., Antoniou X., Sclip A., Grande V., Cardinetti D., Colombo A., Canu N., Benussi L., Ghidoni R., Forloni G., Borsello T. JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. J. Alzheimers Dis. 2011, 26:315-329.
49. Ren Q.G., Liao X.M., Wang Z.F., Qu Z.S., Wang J.Z. The involvement of glycogen synthase kinase-3 and protein phosphatase-2A in lactacystin-induced tau accumulation. FEBS Lett. 2006, 580:2503-2511.
50. Ross C.A., Pickart C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004, 14:703-711.
51. Seltman R., Matthews B. Frontotemporal Lobar Degeneration. CNS Drugs 2012, 26:841-870.
52. Stefanova N., Kaufmann W., Humpel C., Poewe W., Wenning G. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol. 2012, 124:51-65.
53. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., Raman R., Davies P., Masliah E., Williams D.S., Goldstein L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
54. Szweda P.A., Friguet B., Szweda L.I. Proteolysis, free radicals, and aging. Free Radic. Biol. Med. 2002, 33:29-36.
55. Takahashi R.H., Milner T.A., Li F., Nam E.E., Edgar M.A., Yamaguchi H., Beal M.F., Xu H., Greengard P., Gouras G.K. Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 2002, 161:1869-1879.
56. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
57. Tseng B.P., Green K.N., Chan J.L., Blurton-Jones M., LaFerla F.M. Aβ inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 2008, 29:1607-1618.
58. Valera A.G., Díaz-Hernández M., Hernández F., Lucas J.J. Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. Brain Res. Bull. 2007, 72:121-123.
59. Viana R.J.S., Ramalho R.M., Nunes A.F., Steer C.J., Rodrigues C.M.P. Modulation of amyloid-β peptide-induced toxicity through inhibition of JNK nuclear localization and caspase-2 activation. J. Alzheimers Dis. 2010, 22:557-568.
60. Wang Y., Martinez-Vicente M., Kruger U., Kaushik S., Wong E., Mandelkow E.-M., Cuervo A.M., Mandelkow E. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum. Mol. Genet. 2009, 18:4153-4170.
61. Wehland J., Weber K. Turnover of the carboxy-terminal tyrosine of alpha-tubulin and means of reaching elevated levels of detyrosination in living cells. J. Cell Sci. 1987, 88:185-203.
62. Yen S.S. Proteasome degradation of brain cytosolic tau in Alzheimer's disease. Int. J. Clin. Exp. Pathol. 2011, 4:385-402.
63. Young K.F., Pasternak S.H., Rylett R.J. Oligomeric aggregates of amyloid β peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the α7 nicotinic receptor. Neurochem. Int. 2009, 55:796-801.
64. Zhai Q., Wang J., Kim A., Liu Q., Watts R., Hoopfer E., Mitchison T., Luo L., He Z. Involvement of the ubiquitin-proteasome system in the early stages of Wallerian degeneration. Neuron 2003, 39:217-225.